Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. This compound shows potential in treating pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, and multiple myeloma (MM) osteolytic lesions [1] [2] [3] [4] [5].
Description | Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. This compound shows potential in treating pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, and multiple myeloma (MM) osteolytic lesions [1] [2] [3] [4] [5]. |
Molecular Weight | N/A |
CAS No. | 1001080-50-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sotatercept 1001080-50-7 inhibitor inhibit